**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 46796

**Manuscript Type:** EDITORIAL

**Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun**

Karras SN *et al*.Adjunctive therapies in T1D

Spyridon N Karras, Theocharis Koufakis, Pantelis Zebekakis, Kalliopi Kotsa

**Spyridon N Karras, Theocharis Koufakis, Pantelis Zebekakis, Kalliopi Kotsa,** Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki 55535, Greece

**ORCID number:** Spyridon N Karras (0000-0002-4225-2746); Theocharis Koufakis (0000-0002-5853-1352); Pantelis Zebekakis (0000-0001-8821-406X); Kalliopi Kotsa (0000-0003-2376-740X).

**Author contributions:** Karras SN and Koufakis T conceived the study, reviewed the literature and drafted the manuscript; Zebekakis P and Kotsa K reviewed the literature and revised the manuscript; all authors approved the final version of the article.

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Spyridon N Karras, MD, PhD, Academic Fellow,**  Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki 55535, Greece. karraspiros@yahoo.gr

**Telephone: +**30-693-2412914

**Received:** February 24, 2019

**Peer-review started:** February 26, 2019

**First decision:** March 11, 2019

**Revised:** March 13, 2019

**Accepted:** March 26, 2019

**Article in press:** March 26, 2019

**Published online:** April 15, 2019

**Abstract**

Treatment of type 1 diabetes (T1D) is currently based exclusively on insulin replacement therapy. However, there is a need for better glycemic control, lower hypoglycemia rates, more effective weight management, and further reduction of cardiovascular risk in people with T1D. In this context, agents from the pharmaceutical quiver of type 2 diabetes are being tested in clinical trials, as adjunctive to insulin therapies for T1D patients. Despite the limited amount of relevant evidence and the inter-class variability, it can be said that these agents have a role in optimizing metabolic control, assisting weight management and reducing glycemic variability in people with T1D. Specific safety issues, including the increased risk of hypoglycemia and diabetic ketoacidosis, as well as the effects of these treatments on major cardiovascular outcomes should be further assessed by future studies, before these therapeutic choices become widely available for T1D management.

**Key words:** Type 1 diabetes; Insulin; Adjunctive therapies; Cardiovascular risk

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Adjunctive to insulin therapies in type 1 diabetes (T1D) may have a role in optimizing metabolic control, assisting weight management and reducing glycemic variability. Specific safety issues should be further assessed by future studies, before these therapeutic choices become widely available for T1D management.

Karras SN, Koufakis T, Zebekakis P, Kotsa K. Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun. *World J Diabetes* 2019; 10(4): 234-240

**URL:** https://www.wjgnet.com/1948-9358/full/v10/i4/234.htm

**DOI:** https://dx.doi.org/10.4239/wjd.v10.i4.234

**INTRODUCTION**

Treatment of type 1 diabetes (T1D) is currently based exclusively on insulin replacement therapy, either by multiple daily injections (MDI) or *via* continuous subcutaneous insulin infusion (“insulin pumps”) and closed-loop (also known as “artificial pancreas”) insulin delivery systems. Whole pancreas and islet cell transplantations are alternative therapeutic options for carefully selected patients meeting specific eligibility criteria; still, these procedures are available only in a few number of specialized centers around the world, thus, being unavailable for the vast majority of people living with T1D[1].

The idea of using agents from the pharmaceutical quiver of type 2 diabetes (T2D) as adjunctive to insulin therapies in T1D is not recent; back in 1985, Gin *et al*[2], published their research on the effects of metformin on insulin sensitivity in patients with T1D and since then, a number of agents from different therapeutic classes have been tested in clinical trials. In the present article, we aim to discuss the rationale behind the use of adjunctive therapies in T1D, strengths and limitations of such an approach, as well as gaps in existing knowledge that deserve further evaluation by future research.

**WHY IS THERE A NEED FOR ADJUNCTIVE THERAPIES IN T1D?**

We live in the era of long- and short-acting insulin analogues (and the very recently introduced ultra-fast acting insulin analogues), which mimic physiological insulin release in a more effective way than human insulin, resulting in better metabolic control and lower hypoglycemia rates, as compared to the latter[3]. Hence, what would adjunctive to insulin treatments contribute more to T1D management in everyday, clinical practice?

First, despite the progress been made during the past years, there is still an imperative need for better glycemic control in people with T1D. Results from a multi-centre, observational, cross-sectional study from Central and Eastern Europe (DEPAC Survey), involving more than 10000 individuals, proved that only 13.1% of T1D patients had glycated hemoglobin A1C (HbA1C) levels within target (< 6.5% / 47.5 mmol/mol)[4]. Mean HbA1C concentration among participants was 8.2% (66.1 mmol/mol), ranging from 7.7% (60.7 mmol/mol) to 9.8% (83.6 mmol/mol) among different countries.

Secondly, it is well established that people with T1D are in a greater risk of developing atherosclerotic disease, compared to the general population[5]. Data from the United Kingdom General Practice Research Database (UK GPRD), indicate a hazard ratio for major cardiovascular disease (CVD) event (myocardial infarction, acute coronary heart disease death, coronary revascularizations, or stroke) of 3.6 (95%CI: 2.9-4.5) in men with T1D and of 7.7 (95%CI: 5.5-10.7) in women with T1D, compared to people without diabetes[6]. Considering the impressive cardioprotective effects that specific agents used in T2D management have demonstrated in recent, randomized clinical trials[7], it is reasonable to consider that these outcomes could be also applicable in T1D populations; however, this is something that remains to be proven by future research.

Thirdly, insulin resistance and adipose tissue inflammation as a result of increased body weight, are key components of T2D pathogenesis[8]. A number of novel agents for T2D management, including glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose co-transporter 2 (SGLT-2) inhibitors, exert optimal effects on body weight, through a variety of acting mechanisms[9]. However, obesity is being increasingly recognized as a major health problem among people with T1D, as well. Results from a prospective study from the United States, where participants with T1D were being followed for a median of 18 years, demonstrated that overweight increased by 47% and the prevalence of obesity increased 7-fold during the above period, with 22.7% of people with T1D having body mass index (BMI) equal or greater to 30 kg/m2[10], at the end of the study. In the same study, only seven percent of patients were on intensive insulin therapy (three or more daily insulin injections) at baseline (1986-1988), in contrast with the end of the follow-up period (2004-2007), when this percentage reached 82%. Therefore, the aforementioned results could be attributed to the increasing rate of the adoption of a “Western” dietary model combined with poor physical activity by a significant proportion of the population worldwide, along with the intensification of insulin therapy during the last decades, which is known to positively correlate with weight gain[11]. It is also known that weight, insulin resistance and CVD risk significantly interplay in people with diabetes. In a prospective cohort study following 603 patients with T1D for 10 years, classic insulin resistance-related factors, including dyslipidemia and waist-to-hip ratio, were found to predict future coronary artery disease events[12], suggesting a strong need for effective management of traditional CVD risk factors, apart from T2D, in T1D as well.

There is data suggesting limitations in insulin availability and affordability in specific areas of the world, particularly for low-income patients[13]. Reduction of insulin dose as a result of adjunctive therapies may prove helpful for those who consider insulin cost as a significant barrier to treatment adherence. Finally, there is no doubt that intensive compared to conventional glycemic control results in lower rates of both micro- and macro-vascular complications in individuals with T1D[14]. However, this can be only achieved at a cost of increased incidence of hypoglycemia[15], which is known to be related with cardiac dysrhythmias, CVD events and death[16]. As a result, clinicians are often required to navigate “through stormy waters” and balance their clinical practice between intensive metabolic control and hypoglycemia, in a way that is not always easy.

**AN OVERVIEW OF AVAILABLE EVIDENCE**

Considering the above, there is an increasing amount of evidence suggesting that adjunctive to insulin treatments may assist glycemic control and weight management in T1D. Metformin has been shown to manifest optimal effects on BMI, total and low-density lipoprotein cholesterol concentrations, and total daily insulin dose (TDD), still not on HbA1C, which following a transient reduction during the first months of therapy, returns to its baseline values[17]. The REMOVAL trial aimed to explore the effects of metformin on carotid intima media thickness (cIMT) in a sample of 428 T1D patients with multiple cardiovascular risk factors, aged over 40 years[18]. Progression of mean cIMT was not significantly reduced with metformin, although maximal cIMT was significantly lower in the metformin group, as compared to placebo. Furthermore, metformin use has been linked to an increasing trend of the incidence of hypoglycemia[19], a clue that requires further assessment by additional studies, particularly with the use of Continuous Glucose Monitoring systems. Overall, existing data do not support that metformin may improve glycemic control, though it might have a wider role in reducing CVD risk in people with T1D.

Dipeptidyl peptidase-4 (DPP-4) inhibitors have been tested in a very small numbers of trials and safe conclusions regarding these agents cannot be drawn. Their impact on glycemic control, seems to be non-significant[20]; nevertheless, there is preliminary data indicating that sitagliptin might lower postprandial glucose levels in patients treated with a closed-loop system[21] and preserve beta-cell function in individuals with slowly progressive T1D[22]. In addition, DPP-4 inhibitors probably exert some important immunoregulatory actions[23], thus, deserving further evaluation as adjunctive treatments in T1D or other autoimmune types of diabetes [Latent Autoimmune Diabetes in Adults (LADA), for example].

GLP-1 agonists have been demonstrated to significantly reduce HbA1C, body weight and TDD (particularly bolus doses), when used in people with T1D[24]. However, some studies raised concerns regarding their safety. In ADJUNCT ONE trial, 1398 patients with T1D were randomized to receive either liraglutide at varying doses or placebo, on top of insulin whose dose was adjusted according to a treat-to-target protocol over 52 wk[25]. Symptomatic hypoglycemia was increased in all liraglutide groups as compared to placebo. Hyperglycemia with ketosis was more frequent in the group of patients receiving liraglutide at 1.8 mg, probably due to nausea related to its use and concomitant reduction of insulin dose. Similar reductions in HbA1C, BMI and insulin dose have been observed with pramlintide, an injectable synthetic amylin analogue, being the only drug approved by the United States Food and Drug Administration, as an adjunctive to insulin therapy in T1D[26]. Its use in everyday practice is limited by the fact that it should be subcutaneously administered three to four times a day before meals, being nonpractical for patients already on MDI regimens.

Probably, the most promising results in the field are coming from studies conducted with SGLT-2 inhibitors. These agents seem to contribute to better glycemic control, lower body weight and insulin dose and most importantly, without increasing hypoglycemia rates[27]. In addition, preliminary evidence suggests that they reduce glycemic variability[28], a parameter that is being increasingly recognized to be related to the development of diabetic complications[29]. On the other hand, a systematic review and meta-analysis of ten studies using SGLT-2 inhibitors on top of insulin in T1D, pointed towards an increased risk of diabetic ketoacidosis (DKA) in patients treated with these agents versus placebo[27]. The review identified 16 incidents of both hyperglycemic and normoglycemic DKA in a total of 581 patients. Similar to the clinical experience from the use of SGLT-2 inhibitors in people with T2D, a consistent increase in the incidence of genital tract infections, particularly among females, has been documented in individuals with T1D, as well[30]. As a result, gains and risks should be carefully balanced prior to the use of these drugs in everyday practice. Table 1 summarizes the main advantages and pitfalls of the use of various therapeutic classes as adjunctive treatments in T1D.

**A CRITICAL APPRAISAL OF RELEVANT STUDIES**

The aforementioned results should be interpreted with caution, given that relevant data manifest specific weaknesses. First, the number of studies and patients involved is limited, rendering the extraction of definite conclusions challenging. Secondly, most of relevant studies have been designed to explore “conventional” outcomes, such as changes in HbA1C, body weight and insulin dose. Data on glycemic variability, insulin resistance and oxidative stress markers are scarce, being inversely proportional to the significance that these parameters are gradually gaining, regarding their contribution to the development of diabetes complications.

Moreover, all of these studies are considering people with T1D as an homogenous group of patients, who will overall get - or not get - benefit from adjunctive therapies[31]. It is well established that some people with autoimmune diabetes (either long-term T1D or LADA) share common pathophysiological and phenotypic features with T2D, thus, being difficult to draw the borderline between distinct diabetes types, in these cases[32]. The need for individualized treatment approaches is emphatically highlighted by the paradigm of thiazolidinedione use in T1D; when pioglitazone was added on insulin in lean adolescents with T1D, it had no remarkable effect on glycemic control. In contrast, it resulted in a significant weight gain (+ 3.8 kg), as compared to placebo[33]. Differently, rosiglitazone significantly decreased both HbA1C and TDD, when it was administered in overweight subjects with T1D, where insulin resistance had an apparently important pathogenetic role in the development of metabolic disarrangement[34].

Finally, trials with “hard” CVD end points in T1D populations are currently lacking, being necessary to clarify whether the remarkable effects of specific agents on CVD morbidity and mortality in people with T2D, can be translated to respective CVD benefits in people with T1D. Table 2 summarizes the main limitations of available evidence on the use of various drugs as adjunctive treatments in T1D.

**FUTURE CLINICAL RESEARCH STUDIES**

Despite the initial enthusiasm for potential clinical implications of immunotherapy in T1D, research in the field has so far failed to prevent the onset or to reverse autoimmune diabetes[35]. Stem cell therapies, immune ablation and standard immunosuppressants have been tested in several studies, nevertheless not being able to confirm the expectations derived from animal models, at least for the moment. Immune prevention strategies have tested low insulin doses and alternative administration routes (*e.g*., oral insulin) to prevent diabetes in individuals at high risk of T1D, still showed no remarkable benefit[36]. Studies using non-antigen specific immunosuppressive drugs demonstrated encouraging results in prolonging remission of T1D; however, at a cost of toxicity and side effects[37]. Leptin might prove useful in suppressing glucagon concentrations[38], but clinical benefits of its use in T1D should be further evaluated by clinical trials. As a result, safety and efficacy of these treatments in T1D remain an area for forthcoming studies.

**CONCLUSION**

In conclusion, despite the limitations of available evidence and the inter-class variability, adjunctive to insulin therapies may have a role in optimizing metabolic control, assisting weight management and reducing glycemic variability in people with T1D. Specific safety issues, including the increased risk of hypoglycemia and DKA, as well as the effects of these treatments on major cardiovascular outcomes should be further assessed by future studies, before these therapeutic choices become widely available for T1D management.It seems that for both physicians and people with T1D, a fascinating journey to the land of pharmacologic adjunctive to insulin therapies has just begun.

**REFERENCES**

1 **Gamble A**, Pepper AR, Bruni A, Shapiro AMJ. The journey of islet cell transplantation and future development. *Islets* 2018; **10**: 80-94 [PMID: 29394145 DOI: 10.1080/19382014.2018.1428511]

2 **Gin H**, Messerchmitt C, Brottier E, Aubertin J. Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. *Metabolism* 1985; **34**: 923-925 [PMID: 4046836 DOI: 10.1016/0026-0495(85)90139-8]

3 **Kalra S**, Gupta Y. Ultra-fast acting insulin analogues. *Recent Pat Endocr Metab Immune Drug Discov* 2014; **8**: 117-123 [PMID: 25022572 DOI: 10.2174/1872214808666140714112644]

4 **Andel M**, Grzeszczak W, Michalek J, Medvescek M, Norkus A, Rasa I, Niewada M, Kamiński B, Kraml P, Madacsy L; DEPAC Group. A multinational, multi-centre, observational, cross-sectional survey assessing diabetes secondary care in Central and Eastern Europe (DEPAC Survey). *Diabet Med* 2008; **25**: 1195-1203 [PMID: 19046198 DOI: 10.1111/j.1464-5491.2008.02570.x]

5 **Donaghue K**, Jeanne Wong SL. Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus. *Curr Diabetes Rev* 2017; **13**: 533-543 [PMID: 28120713 DOI: 10.2174/1573399813666170124095113]

6 **Soedamah-Muthu SS**, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. *Diabetes Care* 2006; **29**: 798-804 [PMID: 16567818]

7 **Lawrence L**, Menon V, Kashyap S. Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients. *Curr Cardiol Rep* 2018; **20**: 65 [PMID: 29926285 DOI: 10.1007/s11886-018-1005-8]

8 **Naidoo V**, Naidoo M, Ghai M. Cell- and tissue-specific epigenetic changes associated with chronic inflammation in insulin resistance and type 2 diabetes mellitus. *Scand J Immunol* 2018; **88**: e12723 [PMID: 30589455 DOI: 10.1111/sji.12723]

9 **Srivastava G**, Fox CK, Kelly AS, Jastreboff AM, Browne AF, Browne NT, Pratt JSA, Bolling C, Michalsky MP, Cook S, Lenders CM, Apovian CM. Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity. *Obesity* (Silver Spring) 2019; **27**: 190-204 [PMID: 30677262 DOI: 10.1002/oby.22385]

10 **Conway B**, Miller RG, Costacou T, Fried L, Kelsey S, Evans RW, Orchard TJ. Temporal patterns in overweight and obesity in Type 1 diabetes. *Diabet Med* 2010; **27**: 398-404 [PMID: 20536510 DOI: 10.1111/j.1464-5491.2010.02956.x]

11 **Kolb H**, Stumvoll M, Kramer W, Kempf K, Martin S. Insulin translates unfavourable lifestyle into obesity. *BMC Med* 2018; **16**: 232 [PMID: 30541568 DOI: 10.1186/s12916-018-1225-1]

12 **Orchard TJ**, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. *Diabetes Care* 2003; **26**: 1374-1379 [PMID: 12716791 DOI: 10.2337/diacare.26.5.1374]

13 **Li Z**, Feng Q, Kabba JA, Yang C, Chang J, Jiang M, Zhao M, Yu J, Xu S, Li Q, Zhai P, Fang Y. Prices, availability and affordability of insulin products: a cross-sectional survey in Shaanxi Province, western China. *Trop Med Int Health* 2019; **24**: 43-52 [PMID: 30307681 DOI: 10.1111/tmi.13167]

14 **Kähler P**, Grevstad B, Almdal T, Gluud C, Wetterslev J, Lund SS, Vaag A, Hemmingsen B. Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. *BMJ Open* 2014; **4**: e004806 [PMID: 25138801 DOI: 10.1136/bmjopen-2014-004806]

15 **Fullerton B**, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. *Cochrane Database Syst Rev* 2014; **(2)**: CD009122 [PMID: 24526393 DOI: 10.1002/14651858.CD009122.pub2]

16 **Paty BW**. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes. *Can J Diabetes* 2015; **39** Suppl 5: S155-S159 [PMID: 26654859 DOI: 10.1016/j.jcjd.2015.09.009]

17 **Al Khalifah RA**, Alnhdi A, Alghar H, Alanazi M, Florez ID. The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: A systematic review and meta-analysis. *Pediatr Diabetes* 2017; **18**: 664-673 [PMID: 28145083 DOI: 10.1111/pedi.12493]

18 **Petrie JR**, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM; REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol* 2017; **5**: 597-609 [PMID: 28615149 DOI: 10.1016/S2213-8587(17)30194-8]

19 **Abdelghaffar S**, Attia AM. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. *Cochrane Database Syst Rev* 2009; **(1)**: CD006691 [PMID: 19160294 DOI: 10.1002/14651858.CD006691.pub2]

20 **Wang Q**, Long M, Qu H, Shen R, Zhang R, Xu J, Xiong X, Wang H, Zheng H. DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *J Diabetes Res* 2018; **2018**: 5308582 [PMID: 29507862 DOI: 10.1155/2018/5308582]

21 **Underland LJ**, Ilkowitz JT, Katikaneni R, Dowd A, Heptulla RA. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes. *J Diabetes Sci Technol* 2017; **11**: 602-610 [PMID: 28349708 DOI: 10.1177/1932296817699847]

22 **Awata T**, Shimada A, Maruyama T, Oikawa Y, Yasukawa N, Kurihara S, Miyashita Y, Hatano M, Ikegami Y, Matsuda M, Niwa M, Kazama Y, Tanaka S, Kobayashi T. Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S). *Diabetes Ther* 2017; **8**: 1123-1134 [PMID: 28929327 DOI: 10.1007/s13300-017-0299-7]

23 **Ding L**, Gysemans CA, Stangé G, Heremans Y, Yuchi Y, Takiishi T, Korf H, Chintinne M, Carr RD, Heimberg H, Pipeleers D, Mathieu C. Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice. *PLoS One* 2014; **9**: e107935 [PMID: 25268801 DOI: 10.1371/journal.pone.0107935]

24 **Wang W**, Gao Y, Chen D, Wang C, Feng X, Ran X. Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. *Diabetes Res Clin Pract* 2017; **129**: 213-223 [PMID: 28552612 DOI: 10.1016/j.diabres.2017.05.007]

25 **Mathieu C**, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B; ADJUNCT ONE Investigators. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. *Diabetes Care* 2016; **39**: 1702-1710 [PMID: 27506222 DOI: 10.2337/dc16-0691]

26 **Lee NJ**, Norris SL, Thakurta S. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus. *Ann Fam Med* 2010; **8**: 542-549 [PMID: 21060125 DOI: 10.1370/afm.1174]

27 **Chen J**, Fan F, Wang JY, Long Y, Gao CL, Stanton RC, Xu Y. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. *Sci Rep* 2017; **7**: 44128 [PMID: 28276512 DOI: 10.1038/srep44128]

28 **Rodbard HW**, Peters AL, Slee A, Cao A, Traina SB, Alba M. The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes. *Diabetes Care* 2017; **40**: 171-180 [PMID: 27899497 DOI: 10.2337/dc16-1353]

29 **Lu J**, Ma X, Zhang L, Mo Y, Ying L, Lu W, Zhu W, Bao Y, Zhou J. Glycemic variability assessed by continuous glucose monitoring and the risk of diabetic retinopathy in latent autoimmune diabetes of the adult and type 2 diabetes. *J Diabetes Investig* 2018 [PMID: 30306722 DOI: 10.1111/jdi.12957]

30 **Henry RR**, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. *Diabetes Care* 2015; **38**: 2258-2265 [PMID: 26486192 DOI: 10.2337/dc15-1730]

31 **Warnes H**, Helliwell R, Pearson SM, Ajjan RA. Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward? *Diabetes Ther* 2018; **9**: 1831-1851 [PMID: 30209797 DOI: 10.1007/s13300-018-0496-z]

32 **Koufakis T**, Karras SN, Zebekakis P, Kotsa K. Results of the First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults further highlight the need for a novel diabetes classification system. *Ann Transl Med* 2018; **6**: S102 [PMID: 30740423 DOI: 10.21037/atm.2018.11.40]

33 **Zdravkovic V**, Hamilton JK, Daneman D, Cummings EA. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. *J Pediatr* 2006; **149**: 845-849 [PMID: 17137905 DOI: 10.1016/j.jpeds.2006.08.049]

34 **Strowig SM**, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. *Diabetes Care* 2005; **28**: 1562-1567 [PMID: 15983301 DOI: 10.2337/diacare.28.7.1562]

35 **Frumento D**, Ben Nasr M, El Essawy B, D'Addio F, Zuccotti GV, Fiorina P. Immunotherapy for type 1 diabetes. *J Endocrinol Invest* 2017; **40**: 803-814 [PMID: 28260183 DOI: 10.1007/s40618-017-0641-y]

36 **Skyler JS**, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. *Diabetes Care* 2005; **28**: 1068-1076 [PMID: 15855569 DOI: 10.2337/diacare.28.5.1068]

37 **Feutren G**, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Du Rostu H, Rodier M, Sirmai J, Lallemand A. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. *Lancet* 1986; **2**: 119-124 [PMID: 2873396 DOI: 10.1016/S0140-6736(86)91943-4]

38 **Wang MY**, Chen L, Clark GO, Lee Y, Stevens RD, Ilkayeva OR, Wenner BR, Bain JR, Charron MJ, Newgard CB, Unger RH. Leptin therapy in insulin-deficient type I diabetes. *Proc Natl Acad Sci USA* 2010; **107**: 4813-4819 [PMID: 20194735 DOI: 10.1073/pnas.0909422107]

**P-Reviewer:** Koch TR **S-Editor:** Ji FF **L-Editor:** A **E-Editor: Zhang YL**

**Specialty type:** Endocrinology and metabolism

**Country of origin:** Greece

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Advantages and pitfalls of the use of various therapeutic classes as adjunctive treatments in type 1 diabetes**

|  |  |  |
| --- | --- | --- |
| **Therapeutic class** | **Advantages** | **Pitfalls** |
| **Biguanides (metformin)** | Optimal effects on body weight, lipid concentrations and insulin dose | Effect on HbA1C not sustainable over time. Potentially greater risk of hypoglycemia |
| **DPP-4 inhibitors** | Immunoregulatory actions. Potential role in preserving beta-cell function. Good safety profile | Non-significant effect on HbA1C |
| **GLP-1 agonists** | Significant reductions in HbA1C, body weight and insulin dose (particularly bolus doses) | Greater risk of hypoglycemia and DKA |
| **Amylin analogues (pramlintide)** | FDA approved. Significant reductions in HbA1C, body weight and insulin dose (particularly bolus doses) | It should be subcutaneously administered 3-4 times/d |
|  **SGLT-2 inhibitors** | Optimal effects on HbA1C, body weight, insulin dose and glycemic variability. They do not increase risk of hypoglycemia | Increased risk of DKA and genital tract infections |
| **Thiazolidinediones** | Reduction in HbA1C and insulin dose in insulin-resistant T1D patients | Weight gain. Not effective in lean patients |

HbA1C: Glycated hemoglobin A1C; DPP-4: Dipeptidyl peptidase-4; GLP-1: Glucagon-like peptide-1; FDA: United States Food and Drug Administration; SGLT-2: Sodium-glucose co-transporter 2; T1D: Type 1 diabetes; DKA: Diabetic ketoacidosis.

**Table 2 Main limitations of available evidence on the use of various drugs as adjunctive treatments in type 1 diabetes**

|  |  |
| --- | --- |
| **Limitations of clinical trials** | Small number of studies and patients involved |
| Heterogeneity in study designs and exploredoutcomes |
| “Conventional” outcomes explored: changes in HbA1C, body weight and insulin dose. Data on glycemic variability, IR and OS markers are scarce |
| Not taking into account the clinical heterogeneity of patients with T1D |
| Trials exploring the effects of adjunctive treatments on “hard” CVD end points in T1D patients are currently unavailable |

HbA1C: Glycated hemoglobin A1C; T1D: Type 1 diabetes; CVD: Cardiovascular disease; IR: Insulin resistance; OS: Oxidative stress.